阿哌沙班在房颤消融卒中风险患者中的应用
前瞻性开放多中心研究比较持续阿哌沙班与维生素K拮抗剂在房颤消融卒中风险患者中的效果,主要复合终点为死亡、卒中或出血,阿哌沙班非劣于VKA,急性小脑病灶与认知功能两组无差异。
要点
- 持续阿哌沙班在房颤消融卒中风险患者中安全有效,主要复合终点非劣于VKA。
- 急性小脑病灶发生率两组相似,认知功能随访末均改善且组间无差异。
- 仍需进一步研究减少消融相关急性脑病灶。
核心结论
- 持续阿哌沙班在房颤消融卒中风险患者中,就出血、卒中和认知功能而言安全有效。
- 需进一步研究以减少消融相关急性脑病灶。
研究设计与样本
- 前瞻性、开放、多中心研究,结局评估盲法,比较持续阿哌沙班(5 mg 每日两次)与维生素K拮抗剂(INR 2-3)。
- 共随机674例患者,中位年龄64岁,女性33%,非阵发性房颤42%,涉及49个中心;633例接受研究药物并消融;335例进行MRI(25个中心,323份可分析扫描)。
主要发现
- 主要复合终点(死亡、卒中或BARC 2-5出血)在阿哌沙班组22/318例,VKA组23/315例,差异-0.38%(90%CI -4.0%至3.3%),非劣效性P=0.0002(预设绝对界值0.075)。
- 包括2例(0.3%)死亡、2例(0.3%)卒中和24例(3.8%)ISTH大出血。
- 急性小脑病灶两组相似:阿哌沙班44/162(27.2%),VKA 40/161(24.8%),P=0.64。
- 随访末认知功能改善(中位1个MoCA单位,P=0.005),组间无差异。
临床怎么用
- 对于房颤消融且存在卒中风险的患者,可考虑持续阿哌沙班抗凝。
- 阿哌沙班在出血、卒中和认知功能方面与VKA相当。
- 消融相关急性脑病灶仍需关注,需进一步研究优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: It is recommended to perform atrial fibrillation ablation with continuous anticoagulation. Continuous apixaban has not been tested. METHODS AND RESULTS: We compared continuous apixaban (5 mg b.i.d.) to vitamin K antagonists (VKA, international normalized ratio 2-3) in atrial fibrillation patients at risk of stroke a prospective, open, multi-centre study with blinded outcome assessment. Primary outcome was a composite of death, stroke, or bleeding (Bleeding Academic Research Consortium 2-5). A high-resolution brain magnetic resonance imaging (MRI) sub-study quantified acute brain lesions. Cognitive function was assessed by Montreal Cognitive Assessment (MoCA) at baseline and at end of follow-up. Overall, 674 patients (median age 64 years, 33% female, 42% non-paroxysmal atrial fibrillation, 49 sites) were randomized; 633 received study drug and underwent ablation; 335 undertook MRI (25 sites, 323 analysable scans). The primary outcome was observed in 22/318 patients randomized to apixaban, and in 23/315 randomized to VKA {difference -0.38% [90% confidence interval (CI) -4.0%, 3.3%], non-inferiority P = 0.0002 at the pre-specified absolute margin of 0.075}, including 2 (0.3%) deaths, 2 (0.3%) strokes, and 24 (3.8%) ISTH major bleeds. Acute small brain lesions were found in a similar number of patients in each arm [apixaban 44/162 (27.2%); VKA 40/161 (24.8%); P = 0.64]. Cognitive function increased at the end of follow-up (median 1 MoCA unit; P = 0.005) without differences between study groups. CONCLUSIONS: Continuous apixaban is safe and effective in patients undergoing atrial fibrillation ablation at risk of stroke with respect to bleeding, stroke, and cognitive function. Further research is needed to reduce ablation-related acute brain lesions.
引用
- Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018. PMID: 29579168. doi:10.1093/eurheartj/ehy176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。